Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
International Journal of Molecular Sciences
|
January 20, 2021
The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia
Naja Nyffenegger, Anna Flace, Cédric Doucerain, et al.
Journal of Medicinal Chemistry
|
February 20, 2004
Structure-activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands
Manja Lang, Richard M Söll, Franz Dürrenberger, et al.
American Journal of Hematology
|
November 2, 2019
Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers
Frank Richard, Jan Jaap van Lier, Bernard Roubert, et al.
The Journal of Clinical Investigation
|
October 23, 2019
Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia
Vania Manolova, Naja Nyffenegger, Anna Flace, et al.
Hemasphere
|
September 13, 2024
The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis
Naja Nyffenegger, Anna Flace, Ahmet Varol, et al.
Haematologica
|
May 11, 2023
Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions
Natarajaswamy Kalleda, Anna Flace, Patrick Altermatt, et al.
Biochemical Pharmacology
|
September 29, 2004
Cell-type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: phospholipase C-mediated responses in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells
Frank M Dautzenberg, Eric Gutknecht, Ilse Van der Linden, et al.
Blood
|
October 22, 2024
Genetic iron overload aggravates, and pharmacological iron restriction improves, MDS pathophysiology in a preclinical study
Ada Antypiuk, S Zebulon Vance, Richa Sharma, et al.
Elife
|
March 21, 2023
Structures of ferroportin in complex with its specific inhibitor vamifeport
Elena Farah Lehmann, Márton Liziczai, Katarzyna Drożdżyk, et al.
Expert Review of Hematology
|
July 29, 2021
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development
John Porter, Ali Taher, Vip Viprakasit, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
International Journal of Molecular Sciences
|
January 20, 2021
The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia
Naja Nyffenegger, Anna Flace, Cédric Doucerain, et al.
Journal of Medicinal Chemistry
|
February 20, 2004
Structure-activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands
Manja Lang, Richard M Söll, Franz Dürrenberger, et al.
American Journal of Hematology
|
November 2, 2019
Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers
Frank Richard, Jan Jaap van Lier, Bernard Roubert, et al.
The Journal of Clinical Investigation
|
October 23, 2019
Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia
Vania Manolova, Naja Nyffenegger, Anna Flace, et al.
Hemasphere
|
September 13, 2024
The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis
Naja Nyffenegger, Anna Flace, Ahmet Varol, et al.
Haematologica
|
May 11, 2023
Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions
Natarajaswamy Kalleda, Anna Flace, Patrick Altermatt, et al.
Biochemical Pharmacology
|
September 29, 2004
Cell-type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: phospholipase C-mediated responses in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells
Frank M Dautzenberg, Eric Gutknecht, Ilse Van der Linden, et al.
Blood
|
October 22, 2024
Genetic iron overload aggravates, and pharmacological iron restriction improves, MDS pathophysiology in a preclinical study
Ada Antypiuk, S Zebulon Vance, Richa Sharma, et al.
Elife
|
March 21, 2023
Structures of ferroportin in complex with its specific inhibitor vamifeport
Elena Farah Lehmann, Márton Liziczai, Katarzyna Drożdżyk, et al.
Expert Review of Hematology
|
July 29, 2021
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development
John Porter, Ali Taher, Vip Viprakasit, et al.
Page
of 2